Clik here to view.
Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a...
SAN DIEGO Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, today announced that the U.S. Food and Drug...
View ArticleClik here to view.
Exscientia荣获Prix Galien USA 2022数字健康解决方案大奖
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)荣幸地宣布，该公司凭借人工智能驱动的精准医疗平台赢得Prix Galien USA 2022“最佳数字健康解决方案”奖。该奖项于周四在纽约市的Prix Galien Forum上颁发。Prix Galien奖项在世界范围内表彰改善人类健康状况的卓越科学创新，是生物制药研究领域倍受瞩目的奖项。...
View ArticleClik here to view.
Clik here to view.
SYNLAB和Microba进一步加强专业合作，并就先进的肠道微生物组检测装置myBIOME扩大战略协议
澳大利亚布里斯班 欧洲医疗诊断服务和专业检测的领导者SYNLAB和复杂肠道微生物组分析的全球领导者Microba Life Sciences (Microba)扩大了战略合作协议，旨在将微生物组检测装置myBIOME推广到欧洲和拉丁美洲更多地域和市场。...
View ArticleClik here to view.
シンラブとマイクローバが両社の専門性を強化し、先進的な腸内細菌叢検査法myBIOMEに関する戦略的契約を拡大
豪ブリスベン 欧州における医療診断サービスと専門検査のリーダー企業であるシンラブと、複雑な腸内微生物叢の解析で世界をリードするマイクローバ・ライフ・サイエンシズ（マイクローバ）は、微生物叢検査法myBIOMEの提供地域・市場を欧州とラテンアメリカの全域に拡大するための戦略的契約を拡大しました。...
View ArticleClik here to view.
Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of...
BOSTON & DAEJEON, South Korea Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the first...
View ArticleClik here to view.
Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU...
BEIJING & SEOUL, South Korea Eucure Biopharma, a China-based clinical-stage biotechnology company focused on the development of antibody therapeutics, announced today that it has entered into a...
View ArticleClik here to view.
百奥赛图全资子公司祐和医药与韩国ISU ABXIS开展基于YH003序列开发三特异性抗体的合作
中国北京与韩国首尔 (美国商业资讯) — 祐和医药，一家立足于中国的临床阶段的生物技术公司，主要聚焦于开发抗体类药物，今日宣布与ISU ABXIS Co., Ltd (“ISU ABXIS”, KOSDAQ:...
View ArticleClik here to view.
Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU...
BEIJING & SEOUL, South Korea Eucure Biopharma, a China-based clinical-stage biotechnology company focused on the development of antibody therapeutics, announced today that it has entered into a...
View ArticleClik here to view.
Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery...
SCHLIEREN, Switzerland & OSAKA, Japan Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the signing of a research and development...
View ArticleClik here to view.
バイオサイトジェンの子会社ユーキュア・バイオファーマがYH003抗体配列を使用した三特異性抗体の開発でイス・アブシスとの提携を発表
北京 & 韓国ソウル 中国を拠点に抗体医薬の開発に傾注する臨床段階バイオテクノロジー企業であるユーキュア・バイオファーマは本日、韓国を拠点にがん免疫療法薬を開発している臨床段階企業であるイス・アブシス(ISU ABXIS Co., Ltd.、KOSDAQ:086890)と協業契約を締結したと発表しました。...
View ArticleClik here to view.
IEEE Open Journal of Engineering in Medicine and Biology Report on New AI...
PISCATAWAY, N.J. IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS) today...
View ArticleClik here to view.
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib)...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has...
View ArticleClik here to view.
BeiGene to Present Dynamic View of Development Programs for Hematologic...
CAMBRIDGE, Mass., & BASEL, Switzerland & BEIJING BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced clinical and real-world data accepted at...
View ArticleClik here to view.
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for...
SAN DIEGO & TOKYO MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global...
View ArticleClik here to view.
Orum Therapeutics Announces Presentation at ASH 2022 Annual Meeting
BOSTON & DAEJEON, South Korea Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation...
View ArticleClik here to view.
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two...
View ArticleClik here to view.
REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022...
TAIPEI, Taiwan REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b...
View ArticleClik here to view.
MaaT Pharma Announces Participation in Scientific and Investor Conferences in...
LYON, France Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
View ArticleClik here to view.
10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that 10 studies on the BTK...
View Article